Arvinas (NASDAQ:ARVN) Shares Down 5.1% – What’s Next?

Shares of Arvinas, Inc. (NASDAQ:ARVN) dropped 5.1% on Friday . The company traded as low as $8.51 and last traded at $8.54. Approximately 439,205 shares traded hands during trading, a decline of 53% from the average daily volume of 925,893 shares. The stock had previously closed at $9.00.

Wall Street Analysts Forecast Growth

ARVN has been the topic of a number of research analyst reports. Citigroup lowered their price target on Arvinas from $28.00 to $19.00 and set a “neutral” rating on the stock in a report on Friday, March 7th. HC Wainwright reiterated a “buy” rating and set a $81.00 price target on shares of Arvinas in a report on Tuesday, March 11th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Arvinas in a report on Friday, February 7th. Stifel Nicolaus lowered their price target on Arvinas from $63.00 to $51.00 and set a “buy” rating on the stock in a report on Wednesday, February 12th. Finally, Wells Fargo & Company set a $26.00 price target on Arvinas and gave the company an “overweight” rating in a report on Wednesday, March 12th. Five equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. Based on data from MarketBeat.com, Arvinas has a consensus rating of “Moderate Buy” and a consensus price target of $37.47.

Arvinas Stock Down 3.6 %

The business has a 50-day simple moving average of $16.44 and a two-hundred day simple moving average of $21.41. The company has a market cap of $596.53 million, a price-to-earnings ratio of -3.14 and a beta of 1.95.

Arvinas (NASDAQ:ARVN) last announced its quarterly earnings results on Tuesday, February 11th. The company reported ($0.63) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.07) by $0.44. Arvinas had a negative return on equity of 33.75% and a negative net margin of 75.51%. During the same period in the previous year, the company earned ($2.53) earnings per share. As a group, equities analysts anticipate that Arvinas, Inc. will post -3.81 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Ian Taylor sold 9,020 shares of the business’s stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $16.71, for a total transaction of $150,724.20. Following the completion of the transaction, the insider now owns 159,121 shares of the company’s stock, valued at approximately $2,658,911.91. The trade was a 5.36 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Noah Berkowitz sold 8,658 shares of the business’s stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $8.59, for a total value of $74,372.22. Following the transaction, the insider now directly owns 110,023 shares of the company’s stock, valued at $945,097.57. This represents a 7.30 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 50,230 shares of company stock valued at $769,402. Insiders own 5.23% of the company’s stock.

Hedge Funds Weigh In On Arvinas

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. GF Fund Management CO. LTD. bought a new position in Arvinas during the fourth quarter valued at about $28,000. KBC Group NV increased its stake in Arvinas by 77.0% during the fourth quarter. KBC Group NV now owns 2,885 shares of the company’s stock valued at $55,000 after acquiring an additional 1,255 shares during the period. Quantbot Technologies LP increased its stake in Arvinas by 147.3% during the third quarter. Quantbot Technologies LP now owns 4,367 shares of the company’s stock valued at $108,000 after acquiring an additional 2,601 shares during the period. KLP Kapitalforvaltning AS bought a new position in Arvinas during the fourth quarter valued at about $171,000. Finally, Tema Etfs LLC bought a new stake in shares of Arvinas in the 4th quarter valued at approximately $227,000. 95.19% of the stock is currently owned by institutional investors.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.